Gender-Diverse Diagnostic Guidance Issued
ADLM releases new US recommendations to improve laboratory test interpretation and diagnostic decision-making for gender-diverse patients
Clinical Scorecard: Gender-Diverse Diagnostic Guidance Issued
At a Glance
Category Detail
Condition Gender-diverse patients receiving hormone therapy Key Mechanisms Hormone therapy alters laboratory test results, complicating interpretation. Target Population Adults receiving gender-affirming hormone therapy for at least six months Care Setting Laboratory medicine and diagnostic services
Key Highlights
First comprehensive US guidance for laboratory services for gender-diverse patients. Recommends personalized diagnostic interpretation considering hormone status. Calls for standardized approaches in transfusion medicine for transgender and nonbinary individuals. Suggests incorporating organ inventories into electronic health records. Emphasizes the use of anatomically accurate, gender-neutral terminology in pathology. Guideline-Based Recommendations
Diagnosis
Use personalized approaches for interpreting laboratory test results. Management
Document both legal sex and affirmed gender identity in laboratory practices. Monitoring & Follow-up
Consider hormone exposure and clinical context in test result interpretation. Risks
Traditional reference intervals may lead to misinterpretation of results. Patient & Prescribing Data
Adults who have received gender-affirming hormone therapy for at least six months.
Guidance provides a framework for adapting diagnostic workflows.
Clinical Best Practices
Incorporate relevant anatomy and preventive screening decisions into laboratory findings. Standardize practices in transfusion medicine for gender-diverse donors and recipients. Related Resources & Content
